Principal Investigators


    Contact information of lead PI


    European Commission

    Title of project or programme

    Toxic protein aggregation in neurodegeneration

    Source of funding information

    European Commission FP7-Seventh Framework Programme

    Total sum awarded (Euro)

    € 13,927,098

    Start date of award


    Total duration of award in years


    The project/programme is most relevant to:

    Neurodegenerative disease in general


    Research Abstract

    Formation of amyloid-like protein aggregates is the hallmark of a number of neurodegenerative diseases, but how the aggregation process is linked with cytotoxicity and cell death remains unclear. The goal of this pro¬ject is to elucidate the basic mechanisms of aggregate toxicity and how it affects the biological system in its entirety. We will analyse cell culture and mouse models of Huntington’s disease, amyotrophic lateral sclero¬sis and Alzheimer’s disease using a trans-disciplinary approach combining cellular biochemistry, quantita¬tive proteomics and 3D cryo-electron tomography. The effects of aggregating protein species (APS) formed by designer proteins and authentic disease proteins will be compared to define general and disease-specific toxicity mechanisms. The main aims of this project are:
    1. To determine the sequence of cellular events occurring during toxic protein aggregation. Live cell imaging and single molecule fluorescence fluctuation measurements will be employed to monitor how APS evolve from diffusible oligomers to large inclusions and quantitative proteomics will define signatures for cells with different forms of aggregates.
    2. To identify the mechanisms of aggregation toxicity through a systematic interactome analysis of APS in cell culture and mouse brain. The cellular localization of APS and their potential association with membrane structures and cellular machinery will be determined by cryo-ET.
    3. To elucidate why cellular protein quality control fails in neurodegenerative disease. Specially designed proteostasis sensors will be used to monitor the status of the protein folding machinery as aggregate pathol¬ogy develops. The potentially protective pathways of inclusion body formation will be explored using cryo-ET and laser capture dissection coupled with highly sensitive proteomics.
    Understanding aggregation toxicity will be invaluable in developing novel therapeutic strategies for some of the most debilitating diseases of our time.

    Lay Summary

    Further information available at:

Types: Investments > €500k
Member States: European Commission
Diseases: Neurodegenerative disease in general
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF